Vaxcyte (PCVX) Total Current Liabilities (2019 - 2026)
Vaxcyte (PCVX) posted quarterly Total Current Liabilities of $242.1 million for Q1 2026, up 149.58% year-over-year from $97.0 million in Q1 2025, and up 17.66% quarter-over-quarter from $205.8 million in Q4 2025.
Vaxcyte (PCVX) Total Current Liabilities (2019 - 2026) Analysis & Trends
Vaxcyte (PCVX) has reported Total Current Liabilities for 8 consecutive years, with $242.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 149.58% year-over-year to $242.1 million; the TTM figure through Mar 2026 stood at $242.1 million (up 149.58% YoY), while the FY2025 annual figure was $205.8 million, up 46.78% from the prior year.
- Total Current Liabilities grew to $242.1 million in Q1 2026 per PCVX's latest filing, from $205.8 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $242.1 million in Q1 2026 and bottomed at $27.2 million in Q1 2022.
- Historically, Total Current Liabilities has averaged $106.7 million across 5 years, with a median of $87.1 million in 2024.
- Annual changes were most pronounced in 2022 — Total Current Liabilities sank 50.47% — and 2023, when it soared 258.64%.
- Vaxcyte's Total Current Liabilities stood at $40.5 million in 2022, then jumped by 258.64% to $145.3 million in 2023, then declined by 3.55% to $140.2 million in 2024, then jumped by 46.78% to $205.8 million in 2025, then climbed by 17.66% to $242.1 million in 2026.
- Business Quant data shows PCVX's Total Current Liabilities at $242.1 million in Q1 2026, $205.8 million in Q4 2025, and $200.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Vaxcyte | 8.41 Bn | 8.41 Bn | - | 271.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 271.28 Mn |
| Mar 31, 2026 | 242.08 Mn |
| Dec 31, 2025 | 205.75 Mn |
| Sep 30, 2025 | 200.05 Mn |
| Jun 30, 2025 | 154.49 Mn |
| Mar 31, 2025 | 97.00 Mn |
| Dec 31, 2024 | 140.18 Mn |
| Sep 30, 2024 | 123.79 Mn |
| Jun 30, 2024 | 82.85 Mn |
| Mar 31, 2024 | 87.10 Mn |
| Dec 31, 2023 | 145.34 Mn |
| Sep 30, 2023 | 85.56 Mn |
| Jun 30, 2023 | 60.22 Mn |
| Mar 31, 2023 | 52.75 Mn |
| Dec 31, 2022 | 40.53 Mn |
| Sep 30, 2022 | 39.31 Mn |
| Jun 30, 2022 | 30.47 Mn |
| Mar 31, 2022 | 27.25 Mn |
| Dec 31, 2021 | 28.72 Mn |
| Sep 30, 2021 | 47.46 Mn |